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Abstract
Sixty patients with stages II-III AH 
were studied. ABPM was performed in all 
the patients. DBPP was assessed by the 
degree of nocturnal BP lowering. Patients 
were randomized into groups receiving 
perindopril or losartan potassium. Perindopril 
was prescribed at a dose of 4 mg/day with 
subsequent rising up to 8 mg/day during 7 
days. The initial dose of losartan potassium 
was 25 mg with subsequent rising up to 50 
mg 2 times a day. The duration of observation 
was 8 weeks. Thus, perindopril therapy in 
hypertensive patients in the preoperative 
CABG period increased the number of 
people with normal BP profile.
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Introduction. Arterial hypertension (AH) 
remains one of the most significant non- 
communicable pandemics in human history, 
determining the structure of cardiovascular (CV) 
disease and mortality. Moreover, prolonged
Аннотация
Проведено исследование 60 больных
3 стадии АГ. Пациентам проведено суточ­
ное мониторирование артериального дав­
ления с оценкой суточного профиля АД по 
степени снижения ночного АД. Обследо­
ванные больные были рандомизированы в 
группы получавшие периндоприл и лозар- 
тан калия. Периндоприл назначали в дозе
4 мг/сут с последующей титрацией дозы до 
8 мг/сут в течение 7 дней. Стартовая доза 
лозартана калия составила 50 мг/сут с по­
следующей титрацией до 100 мг/сут в два 
приема. Длительность исследования со­
ставила 8 недель. В нашем исследовании 
установлено, что у больных гипертониче­
ской болезнью в предоперационном пери­
оде АКШ назначение периндоприла при­
водит к увеличению количества пациентов 
с нормальным профилем АД.
Ключевые слова: артериальная ги­
пертензия, артериальное давление, амбу­
латорное мониторирование артериального 
давления, периндоприл, лозартан калия, 
аортокоронарное шунтирование.
elevation of arterial blood pressure (BP) 
causes myocardial remodeling with worsening 
perfusion, accelerating of atherosclerotic 
processes in the arteries. Thus, the latter 
leads to the development of ischemic heart
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disease (IHD), cardiosclerosis and heart failure
[1]. Target organ damage including the heart 
and blood vessels in hypertensive disease is 
determined by the presence of AH. But in its 
turn it correlates more closely with ambulatory 
blood pressure monitoring (ABPM) parameters, 
such as high absolute values, variability 
during the day as well as blood pressure load
[2]. Additionally, the target organ damage is 
associated with circadian rhythm of BP.
Based on these reasons, the goal of 
therapeutic effects should be in achieving the 
target BP less than 140/90 mm Hg as well 
as desensitization of resistive type arteries to 
presser effects. Taking this into consideration, 
among antihypertensive drugs the preference 
should be given to the use of inhibitors of 
angiotensin converting enzyme (ACE) inhibitors 
and angiotensin II receptor antagonists (APA) 
which have great opportunities to correct BP 
level [3].
Unlike thiazide derivatives and beta-blockers 
with negative effect on the development of 
atherosclerosis and diabetes, ACE inhibitors 
and ARA represent a class of antihypertensive 
drugs with metabolically neutral effect [4, 5], 
improving endothelial function [6], as well as 
restoring the balance between vasopressor and 
vasodilator systems [7]. In fact, the use of these 
antihypertensive drugs for effective control 
of BP as monotherapy is another important 
aspect of these groups of drugs. The use of 
monotherapy for reaching target BP has many 
advantages, especially in terms of adherence 
to therapy as well as achieving the optimum 
control over treatment. These drugs are also 
recommended for reduction in CV mortality, 
nonfatal myocardial infarction, and stroke, as 
well as the need for coronary angioplasty or 
coronary artery bypass grafting (CABG) [8].
IHD and cerebral stroke are most frequent 
among CV diseases occurring in patients 
with AH. AH and concomitant ischemic heart 
disease increase the risk of morbidity and 
mortality twofold and fall under a very high 
risk category by Framingham criteria (USA) 
and SCORE (European Society of Cardiology)
regardless of BP. Cerebral vascular events 
in patients who underwent CABG as well as 
higher incidence of neurological disorders 
(0.4% to 80%, depending on the diagnostic 
method) present a significant problem in 
cardiology, as hypertension is considered to be 
one of the major causes of postoperative stroke 
and encephalopathy after CABG [9].
ABPM gives the opportunity to reveal and 
identify changes of diurnal BP profile (DBPP) 
of both in terms of detection of high absolute 
values and variability of degree of nocturnal BP 
lowering and pressure load. Direct evidence 
of pathological morning BP raise results in 
increasing mortality from CV causes. Today 
the problem of choice of antihypertensive 
medications affecting DBPP is still challenging.
Objective. A comparative analysis of 
perindopril and losartan potassium effect in 
patients with III stage hypertensive disease 
on ABPM parameters in order to evaluate 
antihypertensive effect of these drugs in 
patients before CABG.
Materials and Methods. Sixty patients with 
III stage hypertensive disease after myocardial 
infarction (in more than 6 months before 
CABG) with stenotic coronary atherosclerosis 
(confirmed by coronary angiography) were 
reviewed. The present study was approved by 
the Ethical Committee and all patients gave 
informed consent. The exclusion criteria of the 
study were: rhythm disturbances in the form 
of frequent ventricular and supraventricular 
extra systoles (more than 6/ min), permanent 
atrial fibrillation; concomitant severe liver 
diseases, kidney, respiratory organs with 
respiratory failure, as well as cancer. All 
patients underwent routine clinical, laboratory 
and instrumental examination including 
physical examination, biochemical blood tests, 
urinalysis, electrocardiography, and ABPM.
Ambulatory BP monitoring was performed 
by means of AVRM-04 Recorder («Meditech», 
Hungary). Average levels of systolic BP 
(SBP), diastolic BP (DBP) and heart rate 
were measured during 24 hours. The time 
index was defined as the percentage of
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BP measurements, during which BP level 
exceeded its threshold (140/90 mm Hg for 
wake hours and 120/80 mm Hg for night time). 
BP variability was calculated as standard 
deviation of 24 h SBP and DBP, daytime 
and nighttime separately. The diurnal profile 
was assessed by the degree of nocturnal BP 
lowering, and is defined as the ratio of the 
difference between the average values of BP 
during awake and sleep hours to the average 
daytime BP values expressed in percentage. 
Values more than 10% and less than 20% were 
taken as normal BP dipping. Concomitant 
therapy included antianginal (nitro agents) 
and antiplatelet agents (acetylsalicylic acid, 
100 mg / day).
Thus, for routine antihypertensive therapy 
after ABPM all the patients were randomized 
into groups receiving perindopril (Perineva, 
KRKA) or losartan potassium (Losap, Zentiva). 
Perindopril was administered at a dose of 4 mg/ 
day with subsequent rising up to 8 mg/day for 7 
days. The initial dosage of losartan potassium 
was 25 mg with subsequent increasing up to 50 
mg 2 times a day (after 7 days of therapy). The 
duration of observation was 8 weeks. Inefficacy 
in therapy was a reason for the exclusion of
patients from the study and appointment of 
a combined therapy. Thus, the frequency of 
achieving target BP (< 140/90 mm Hg) was 
61%.
Statistical analysis of the results was 
performed using the statistical package 
Statistica 6.0 (Statsoft Inc.). The data are given 
as Medians [25%; 75%] (Me [Me (n)-Me (b)]). 
In comparison of the non-normally distributed 
variables, the Mann-Whitney test was used 
to test the differences between two groups. 
For all normally distributed variables, the t-test 
was used for comparison between two groups. 
For correlation analysis, Pearson correlation 
coefficient and Spearman rank correlation 
coefficient were calculated. Scheffe method of 
linear contrasts was applied to detect all possible 
contrasts in individual groups as well as Fisher 
exact test -  while comparing the frequency of 
adverse changes in the CV system [10].
Results of the study.
The average age of the patients was 56 (50; 
60). Distribution of the patients according to 
the stage of hypertension and the presence of 
comorbidities and complications are presented 
in Table 1.
Table 1
Clinical characteristics o f patients with AH
Indicator
Perindopril Losartan potassium
n=35 n=25
Age, years 
Ме [25%; 75%] 54 (50; 60) 58 (51; 60)
AH duration, years 8.0 (5.0; 16.0) 12.0 (8.0; 16.0)
AH stage:
Stage II Hypertension 23 (65.7%) 15 (60.0%)
Stage III Hypertension 12 (34.0%) 10 (40%)
I FC CHF 12 (34.3%) 13 (52.0%)
II FC 15 (42.8%) 7 (28.0%)
III FC 8 (22.9%) 5 (20.0%)
A comparative analysis of the ambulatory 
monitoring of BP parameters in patients treated 
with perindopril and losartan potassium showed 
the following results (Tab. 2, 3). Perindopril
treatment reduced 24-hour and daytime SBP 
by 17.2% (p<0.0001) as compared to baseline, 
as well as nighttime BP -  by 22.5% (p<0.0001). 
At the same time 24-hour and daytime DBP
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reduced by 18.3% and 17.6% (p<0.0001), 
respectively, whereas night DBP decreased by 
27.2% (p<0.0001) as compared to baseline.
Thus, the pulse pressure and BP variability 
(VBP) of both systolic and diastolic were more 
significant at night, a decrease for SBP was 
26.7% (p = 0.004) and 20.0% (p = 0.045) -  for 
DBP. This was accompanied by decrease in
the number of non-dippers by 24.3% and night- 
peakers by 5.4%, as well as increase in number 
of dippers by 27.0% and over-dippers by 2.7%. 
Diurnal diastolic pressure also increased due 
to the group of dippers by 18.9% (p <0.01) and 
decreased due to non-dippers by 13.5%, night- 
peakers -  by 2.7% as well as over-dippers -  by 
2.7%.
Table 2
ABPMparameters in the treatment with perindopril and losartan potassium
(Me [Me (n) -  Me(b)])
Parameters
Group 1 (n =35) 
Perindopril
Group 2 
Losartan
(n =25) 
>otassium
baseline after 8 weeks baseline after 8 weeks
24-hour 148.0 122.5* 161.5 120.0*
SBP (139.0; 159.0) (118.0; 125.0) (144.0; 168.0) (120.0; 127.0)°
Daytime 152.0 126.0* 165.0 126.0*
SBP (143.0; 166.0) (122.0; 132.0) (150.0; 179.0) (115.0; 131.0)
Nighttime 142.5 110.5* 149.0 111.0*
SBP (132.0; 148.0) (107.0; 116.0) (134.0; 150.0) (108.0; 123.0)
24-hour 90.0 73.5* 99.0 69.0*
DBP (83.0; 93.0) (65.0; 76.0) (87.0; 96.0) (62.0; 74.0) °
Daytime 94.0 77.5* 95.0 73.0*
DBP (85.0; 99.0) (72.0; 83.0) (92.0; 106.0) (70.0; 78.0) °
Nighttime 81.0 59.0* 81.0 66.0*
DBP (73.0; 84.0) (57.0; 67.0) (77.0; 89.0) (52.0; 71.0)
24-hour 63.5 48.0* 69.0 52.0*
PBP (58.5; 68.5) (45.0; 53.0) (64.0; 71.0) (48.5; 56.0)
Daytime 61.0 48.0* 68.0 52.5*
PBP (56.0; 65.0) (45.0; 52.0) (64.0; 73.0) (47.5; 54.0)
Nighttime 64.0 49.0* 19.0 51.5*
PBP (57.0; 71.0) (44.0; 53.0) (62.0; 68.0) (46.0; 57.5)
24-hour 16.0 14.0 67.0 13.0*
SBPV (14.0; 19.0) (12.0; 16.0) (16.0; 25.0) (12.5; 16.0) °
Daytime 15.0 12.0 13.5 13.0
SBPV (13.0; 20.0) (11.0; 14.0) (15.0; 24.0) (11.5; 13.5)
Nighttime 15.0 11.0 16.5 12.0
SBPV (13.0; 18.0) (9.0; 14.0) (12.0; 16.0) (10.5; 16.0) °
24-hour 14.0 13.0 13.5 12.5
DBPV (12.0; 16.0) (11.0; 14.0) (10.0; 18.0) (11.5; 13.0)
Daytime 13.0 11.0 9.0 10.5
DBPV (10.0; 15.0) (10.0; 13.0) (10.0; 15.0) (9.0; 11.5)
Nighttime 10.0 8.0 12.5 10.0
DBPV (8.0; 14.0) (7.0; 11.0) (8.0; 11.0) (9.0; 11.0) °
Notes: ° p<0.04 difference between drugs effect; *  p 2-3, 4-5 <0.0001
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Table 3
Diurnal profile o f SBP and DBP under the influence o f treatment 
withperindopril and losartan potassium
Diurnal
profile
Group 1 (n =35) 
Perindopril
Group 2 
Losartan
(n =25) 
potassium
Р
(after the 
atment)baseline after 8 weeks baseline after 8 weeks
1. 24-hour SBP
Non-dipper 20 (54.1%) 11 (29.7%)* 11 (50.0%) 10 (45.5%) Р=0.027
Dipper 13 (35.1%) 23 (62.2%)* 9 (40.9%) 8 (36.4%) P=0.002
Night-peaker 3 (8.1%) 1 (2.7%)* 2 (9.1%) 4 (18.2%)* P=0.011
Over-dipper 1 (2.7%) 2 (5.4%)* 0 (0) 0 (0) Р=0.030
2. 24-hour DBP
Non-dipper 17 (45.9%) 12 (32.4%)* 10 (45.5%) 9 (40.9%) Р=0.043
Dipper 14 (37.8%) 21 (56.8%)* 8 (36.4%) 10 (45.5%) Р=0.014
Night-peaker 2 (5.4%) 1 (2.7%) 1 (4.5%) 1 (4.5%) Р=0.001
Over-dipper 4 (10.8%) 3 (8.1%) 3 (13.6%) 2 (9.1%) Р=0.032
Note: * p<0.05 compared with the periods before and after the treatment
Thus, the effect of perindopril treatment 
on diurnal rhythm of BP resulted primarily in a 
decrease in diastolic and pulse BP mostly at 
night and to a lesser extent in systolic BP, which 
in its turn led to an increase in the number of 
patients of dipper type. These changes indicate 
an improvement in the functioning of vasodilator 
mechanisms of vascular tone regulation.
The assessment of losartan potassium effect 
on ambulatory BP monitoring after 8 weeks of 
therapy showed that 24-hour SBP reduced as 
compared to baseline by 25.7% (p <0.0001), 
while daytime -  by 23.6% (p <0.0001), nighttime 
-  by 25.5% ( p <0.0001). 24-hour DBP reduced 
by 27.4%, daytime -  by 26.3%, night time - by 
18.5% (p = 0.003); whereas 24-hour pulse BP 
significantly reduced by 24.6% (p = 0.0006), 
daytime -  by 22.8% (p = 0.0004) and nighttime -  
by 23.1% (p = 0.003). The positive dynamics of 
losartan potassium effect on BP during the day 
is evidenced by reduction in the values of 24- 
hour SBPV (up to 31.6%) and daytime DADV (by 
16.0%).
A comparative analysis of the hypotensive 
effect of perindopril and losartan potassium 
therapy showed significantly much greater 
changes in VBP in group treated with losartan
potassium. Moreover, the number of patients with 
SBP corresponding to non-dippers maintained 
at the range of 45.5% in the group treated with 
losartan potassium that significantly (p = 0.027) 
differed from the group treated with perindopril. 
Additionally, a number of dippers for both systolic 
and DBP significantly increased up to 62.2% 
and 56.8%, respectively in group treated with 
perindopril in comparison with losartan therapy.
Thus, a comparative evaluation of the 
hypotensive effect of perindopril and losartan 
potassium therapy suggests that reduced 
DBPP is more preferable in the treatment with 
perindopril with reduction of VBP during the day. 
Antihypertensive effect of losartan potassium 
therapy is more significant in the daytime and 
nighttime, but it is accompanied by lower 24- 
hour VBP, although the number of patients 
corresponding to dippers was significantly less 
as compared to perindopril therapy.
Discussion of the results. The main goal 
in the treatment of AH is to minimize the risk of 
CV complications and death from them [11, 12]. 
The changes in the circadian rhythm of BP can 
lead to pathological hypertensive reactions of 
night peaker, which result in fatal events [13].
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Taking this into consideration, BP level lowering 
as well as an increase in the number of dippers 
are significant tasks of modern cardiology, which 
can affect the reduction of cerebral fatal and 
nonfatal CV events. This applies primarily to 
ACE inhibitors, such as perindopril [14].
According to some researches, the data of 
additional cardioprotective properties of ACE 
inhibitors in IHD patients with AH cannot be 
explained only by the reduction in BP level. It 
is estimated that ACE inhibitors affect the basic 
pathological processes underlying coronary 
heart disease, such as vasoconstriction, 
structural changes in the vascular wall as well 
as left ventricular remodeling. The protective 
effect of ACE inhibitors on the development 
of atherosclerosis is possible due to their 
mechanisms of action. They lead to reducing 
angiotensin II and increasing the production of 
nitric oxide and bradykinin as well as improving 
vascular endothelium functions. One of the 
mechanisms of anti-ischemic action of ACE 
inhibitors is peripheral vasodilatation, eliminating 
the hemodynamic overload of the heart (by both 
filling and resistance), as well as the reduction 
of pressure in the ventricles [15]. In our study, 
we revealed the ability of perindopril to affect 
the transformation of pathogenic mechanisms of 
AH (restore circadian BP rhythm violations) by 
affecting the activity of the renin-angiotensin and 
related sympathetic nervous systems as well 
as by improving the vasoregulating endothelial 
function.
Conclusion. In patients with stage III AH, 
a significant increase in the average 24-hour, 
daytime and nighttime BP values, time index, 
pressure load as well as reduction of nocturnal 
BP lowering were identified. A high liability of 
DBPP with high variability was detected, that 
might be a predictor of acute CV and cerebral 
events. Thus perindopril therapy in hypertensive 
patients in the preoperative CABG period 
increased the number of people with normal 
BP profile. It is necessary to go on investigating 
the vascular and neurohormonal mechanisms 
of pathological remodeling and their relation 
with the efficacy and safety of antihypertensive 
therapy with drugs which normalize circadian 
rhythm of BP that in its turn allows to conduct 
adequate target correction in time.
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